Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.28 Insider Own0.90% Shs Outstand153.78M Perf Week0.61%
Market Cap7.92B Forward P/E104.00 EPS next Y0.50 Insider Trans-11.65% Shs Float152.33M Perf Month-1.04%
Income-195.70M PEG- EPS next Q-0.01 Inst Own- Short Float4.65% Perf Quarter-10.66%
Sales804.40M P/S9.84 EPS this Y9.60% Inst Trans0.01% Short Ratio10.01 Perf Half Y-8.80%
Book/sh7.84 P/B6.57 EPS next Y1350.00% ROA-11.40% Target Price63.33 Perf Year21.50%
Cash/sh3.09 P/C16.66 EPS next 5Y1.20% ROE-16.20% 52W Range41.93 - 63.40 Perf YTD-7.38%
Dividend- P/FCF- EPS past 5Y-6.80% ROI-13.60% 52W High-18.80% Beta2.17
Dividend %- Quick Ratio3.20 Sales past 5Y13.80% Gross Margin81.30% 52W Low22.78% ATR1.20
Employees1750 Current Ratio3.50 Sales Q/Q12.10% Oper. Margin-24.90% RSI (14)51.85 Volatility2.65% 2.22%
OptionableYes Debt/Eq0.24 EPS Q/Q10.10% Profit Margin-24.30% Rel Volume0.73 Prev Close50.75
ShortableYes LT Debt/Eq0.23 EarningsNov 01 BMO Payout- Avg Volume708.05K Price51.48
Recom2.40 SMA200.62% SMA500.59% SMA200-7.78% Volume517,979 Change1.44%
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Oct-16-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
07:00AM  Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting Business Wire
Oct-09-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Oct-06-17 11:17AM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : October 6, 2017 Capital Cube
Oct-05-17 08:10AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 5, 2017 Capital Cube
Oct-04-17 11:51AM  [$$] 6 Top Pharma Picks for Q4 Barrons.com
Sep-28-17 04:00PM  Alkermes Participates in Presidents Commission Meeting on Combating Drug Addiction and the Opioid Crisis Business Wire
08:05AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Sep-27-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Sep-25-17 08:05AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Sep-22-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Sep-19-17 10:37AM  Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Zacks
Sep-18-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
07:00AM  Patients Switched to Alkermes ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA® Business Wire
Sep-12-17 08:08AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Sep-11-17 10:12AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Sep-08-17 11:07AM  [$$] Merck Tops JNJ, Allergan Barrons.com
10:26AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
10:18AM  Three Pharma Stocks To Buy As 2017 Ends With A Whimper Barrons.com
Sep-06-17 10:12AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
07:00AM  Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders Business Wire
Sep-05-17 04:00PM  Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Business Wire
08:05AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
07:00AM  Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress Business Wire
Aug-30-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-29-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-28-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-25-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-24-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-23-17 07:56AM  Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe Zacks
Aug-22-17 11:02AM  Alkermes Initiates Rolling Submission of Depression Drug Zacks
08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-21-17 07:00AM  Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder Business Wire
Aug-16-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-15-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-14-17 04:05PM  ETFs with exposure to Alkermes Plc : August 14, 2017 Capital Cube
08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-13-17 10:30AM  Edited Transcript of ALKS earnings conference call or presentation 27-Jul-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:06AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Aug-11-17 08:06AM  IHS Markit Score downgrades Alkermes PLC to 63 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-10-17 08:07AM  IHS Markit Score upgrades Alkermes PLC to 71 out of 100, despite ranking positively in only one IHS Markit category. Markit
Aug-09-17 08:07AM  See what the IHS Markit Score report has to say about Alkermes PLC. Markit
Jul-31-17 01:42PM  Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017 Capital Cube
Jul-29-17 06:45AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jul-28-17 09:28AM  Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat Zacks
07:27AM  Alkermes Continues to Execute Motley Fool
01:24AM  Alkermes reports 2Q loss Associated Press
Jul-27-17 07:00AM  Alkermes plc Reports Second Quarter 2017 Financial Results Business Wire
Jul-24-17 01:56PM  ETFs with exposure to Alkermes Plc : July 24, 2017 Capital Cube
Jul-20-17 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results Business Wire
Jul-19-17 09:12AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : July 19, 2017 Capital Cube
Jul-14-17 12:43PM  ETFs with exposure to Alkermes Plc : July 14, 2017 Capital Cube
Jul-05-17 11:01AM  Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days Benzinga
08:12AM  Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More Zacks
Jul-04-17 08:58AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : July 4, 2017 Capital Cube
Jul-03-17 09:47AM  Alkermes Presents Phase III Data on Schizophrenia Candidate Zacks
Jun-29-17 04:00PM  Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia Business Wire
Jun-20-17 03:38PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : June 20, 2017 Capital Cube
Jun-19-17 08:54AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 19, 2017 Capital Cube
Jun-12-17 12:00PM  Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying Benzinga
10:47AM  Alkermes Commences Phase III Study for Schizophrenia Drug Zacks
07:00AM  Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
Jun-08-17 04:00PM  Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference Business Wire
07:00AM  Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients Business Wire
Jun-07-17 10:54AM  Alkermes Gets FDA Nod for Two Month Dose of Aristada Zacks
10:01AM  Can Alkermes' Latest Approval Spark a Rally? Motley Fool
Jun-06-17 07:00AM  FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia Business Wire
Jun-05-17 07:47AM  Key FDA Events to Watch Out for in Jun 2017 Zacks
May-31-17 04:12AM  Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue? Zacks
May-30-17 04:20PM  Alkermes Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference Business Wire
07:00AM  Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs Business Wire
May-26-17 08:28AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : May 26, 2017 Capital Cube
May-15-17 03:16PM  Why These Drug Stocks May Surge Investopedia
01:23PM  Big Week Ahead for Alkermes Investopedia
08:20AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : May 15, 2017 Capital Cube
May-11-17 04:00PM  Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting Business Wire
May-04-17 09:08AM  3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018 Motley Fool
May-02-17 11:05AM  [$$] Three Top Picks in Smaller Pharma Barrons.com
08:15AM  Blog Coverage Alkermes Announces Completion of Patient Enrolment in ALKS 3831 Study for the Treatment of Schizophrenia Accesswire
May-01-17 04:11PM  Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo Investor's Business Daily
03:34PM  ETFs with exposure to Alkermes Plc : May 1, 2017 Capital Cube
09:27AM  Alkermes' Revenue Jumps 22% Motley Fool
08:11AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : May 1, 2017 Capital Cube
07:00AM  Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia Business Wire
Apr-28-17 07:55PM  Edited Transcript of ALKS earnings conference call or presentation 27-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
11:11AM  Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
08:51AM  Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss Zacks
Apr-27-17 04:07PM  Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports TheStreet.com
08:56AM  Alkermes reports 1Q loss Associated Press
08:51AM  Biotech Earnings Roundup: Exact Sciences Flying Higher Investopedia
07:00AM  Alkermes plc Reports First Quarter 2017 Financial Results Business Wire
Apr-26-17 04:00PM  Alkermes Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care Conference Business Wire
Apr-20-17 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2017 Financial Results Business Wire
Apr-13-17 12:45PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : April 13, 2017 Capital Cube
Apr-12-17 08:18AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : April 12, 2017 Capital Cube
Apr-07-17 08:47AM  5 Drug Stocks for Your Portfolio this World Health Day Zacks
Apr-04-17 01:20PM  Drug Addiction Treatment Should Start in Emergency Room GuruFocus.com
01:20PM  Drug Addiction Treatment Should Start in Emergency Room
Apr-03-17 04:43PM  Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight Investor's Business Daily
04:43PM  Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL PAUL JDirectorOct 02Option Exercise11.441,50017,1609,500Oct 04 05:06 PM
MITCHELL PAUL JDirectorOct 02Sale50.641,50075,9608,000Oct 04 05:06 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSSep 15Option Exercise15.475,80589,77461,589Sep 18 06:08 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 15Option Exercise14.132503,53331,407Sep 18 05:13 PM
BLOOM FLOYD EDirectorSep 12Option Exercise11.4420,000228,80020,000Sep 14 05:22 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSSep 11Option Exercise14.1313,566191,68870,455Sep 13 05:36 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSSep 11Sale51.2913,566695,81756,889Sep 13 05:36 PM
MITCHELL PAUL JDirectorSep 01Option Exercise11.441,50017,1609,500Sep 05 05:09 PM
MITCHELL PAUL JDirectorSep 01Sale50.771,50076,1558,000Sep 05 05:09 PM
MITCHELL PAUL JDirectorAug 01Option Exercise11.441,50017,1609,500Aug 01 05:12 PM
MITCHELL PAUL JDirectorAug 01Sale54.911,50082,3658,000Aug 01 05:12 PM
MITCHELL PAUL JDirectorJul 03Option Exercise11.441,50017,1609,500Jul 06 05:36 PM
MITCHELL PAUL JDirectorJul 03Sale58.111,50087,1658,000Jul 06 05:36 PM
Cooke ShanePresident, Alkermes plcJun 08Option Exercise16.5510,000165,50084,708Jun 08 05:33 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJun 08Option Exercise17.3010,000173,00054,013Jun 08 05:41 PM
Cooke ShanePresident, Alkermes plcJun 08Sale60.3310,000603,33374,708Jun 08 05:33 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJun 08Sale60.3410,000603,35244,013Jun 08 05:41 PM
MITCHELL PAUL JDirectorJun 01Option Exercise11.441,50017,1609,500Jun 01 05:21 PM
MITCHELL PAUL JDirectorJun 01Sale57.491,50086,2358,000Jun 01 05:21 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMay 28Option Exercise0.003,750058,654May 30 05:16 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 28Option Exercise0.001,750028,163May 30 05:20 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750077,698May 30 05:23 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750058,821May 30 05:30 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 28Option Exercise0.002,5000130,654May 30 05:39 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 28Option Exercise0.001,250031,563May 30 05:42 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000164,870May 30 05:46 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 28Option Exercise0.0013,7500644,156May 30 05:49 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMay 28Option Exercise0.002,500044,013May 30 05:51 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 24Option Exercise15.9525,000398,750655,406May 25 05:34 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 24Sale57.4225,0001,435,535630,406May 25 05:34 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 18Option Exercise15.9510,000159,500172,370May 19 05:58 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 18Sale57.2310,000572,254162,370May 19 05:58 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 17Option Exercise15.9550,000797,500680,406May 19 05:28 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 17Option Exercise15.952,25035,88830,313May 19 05:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 17Sale58.1950,0002,909,439630,406May 19 05:28 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 11Option Exercise15.9510,000159,500172,370May 11 05:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 11Sale57.0110,000570,082162,370May 11 05:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 10Option Exercise15.9525,000398,750655,406May 11 05:03 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 10Sale57.2925,0001,432,244630,406May 11 05:03 PM
Cooke ShanePresident, Alkermes plcMay 04Option Exercise16.556,500107,57578,448May 04 05:26 PM
Cooke ShanePresident, Alkermes plcMay 04Sale60.056,500390,32871,948May 04 05:26 PM
MITCHELL PAUL JDirectorMay 01Option Exercise11.441,50017,1609,500May 03 05:19 PM
Cooke ShanePresident, Alkermes plcMay 01Option Exercise16.553,50057,92575,448May 03 05:30 PM
Cooke ShanePresident, Alkermes plcMay 01Sale60.053,500210,16571,948May 03 05:30 PM
MITCHELL PAUL JDirectorMay 01Sale58.741,50088,1108,000May 03 05:19 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Apr 17Option Exercise16.5510,000165,50065,071Apr 18 05:13 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Apr 17Sale56.6010,000565,98655,071Apr 18 05:13 PM
MITCHELL PAUL JDirectorApr 03Option Exercise11.441,50017,1609,500Apr 04 05:12 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSApr 03Option Exercise15.9515,000239,25069,904Apr 04 05:28 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSApr 03Sale57.6815,000865,23454,904Apr 04 05:28 PM
MITCHELL PAUL JDirectorApr 03Sale58.311,50087,4658,000Apr 04 05:12 PM
Cooke ShanePresident, Alkermes plcMar 29Option Exercise16.362,07033,86974,018Mar 29 05:20 PM
Cooke ShanePresident, Alkermes plcMar 29Sale60.002,070124,20071,948Mar 29 05:20 PM
Cooke ShanePresident, Alkermes plcMar 23Option Exercise15.586,03093,94777,978Mar 27 05:32 PM
Cooke ShanePresident, Alkermes plcMar 23Sale60.016,030361,85671,948Mar 27 05:32 PM
Cooke ShanePresident, Alkermes plcMar 21Option Exercise15.701,60025,11573,548Mar 22 06:45 PM
Cooke ShanePresident, Alkermes plcMar 21Sale60.101,60096,16271,948Mar 22 06:45 PM
Cooke ShanePresident, Alkermes plcMar 20Option Exercise15.903004,77072,248Mar 22 06:45 PM
Cooke ShanePresident, Alkermes plcMar 20Sale60.0030018,00071,948Mar 22 06:45 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 15Option Exercise16.5510,000165,50066,071Mar 16 06:17 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 15Sale56.7411,000624,10755,071Mar 16 06:17 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMar 10Option Exercise12.298,137100,00454,904Mar 10 05:13 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 07Option Exercise16.5525,000413,750144,053Mar 07 05:29 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 07Sale59.0825,0001,477,068119,053Mar 07 05:29 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,812041,513Mar 06 05:50 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000636,523Mar 06 05:47 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8120163,283Mar 06 05:42 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 03Option Exercise0.001,250028,469Mar 06 05:40 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise0.002,8120119,966Mar 06 05:37 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 03Option Exercise0.003,750057,836Mar 06 05:35 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250074,678Mar 06 05:34 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 03Option Exercise0.001,250026,819Mar 06 05:32 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMar 03Option Exercise0.003,500048,414Mar 06 05:31 PM
Cooke ShanePresident, Alkermes plcMar 02Option Exercise14.6020,000292,00089,428Mar 02 05:57 PM
BREYER ROBERT ADirectorMar 02Sale60.004,000240,0007,156Mar 02 05:53 PM
Cooke ShanePresident, Alkermes plcMar 02Sale60.0020,0001,200,00069,428Mar 02 05:57 PM
MITCHELL PAUL JDirectorMar 01Option Exercise11.441,50017,1609,500Mar 02 05:21 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMar 01Option Exercise0.005,750046,970Mar 02 05:47 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250026,300Mar 02 05:55 PM
Cooke ShanePresident, Alkermes plcMar 01Option Exercise0.007,000073,068Mar 02 05:57 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 01Option Exercise0.005,750056,792Mar 02 06:00 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,5000118,615Mar 02 06:04 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250027,950Mar 02 06:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000161,932Mar 02 06:15 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000631,757Mar 02 06:17 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 01Option Exercise0.005,250041,138Mar 02 06:19 PM
MITCHELL PAUL JDirectorMar 01Sale57.061,50085,5908,000Mar 02 05:21 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSFeb 26Option Exercise0.003,750042,437Feb 27 05:32 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100024,407Feb 27 05:34 PM
Cooke ShanePresident, Alkermes plcFeb 26Option Exercise0.004,425068,369Feb 27 05:35 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 26Option Exercise0.003,750052,807Feb 27 05:41 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100026,057Feb 27 05:43 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,6250114,967Feb 27 05:46 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250158,284Feb 27 05:48 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000618,962Feb 27 05:50 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 26Option Exercise0.002,625036,740Feb 27 05:52 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 16Option Exercise16.5510,000165,50059,657Feb 16 05:56 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 16Sale56.5310,000565,27149,657Feb 16 05:56 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 15Sale58.171,00058,17049,657Feb 16 05:56 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise11.441,50017,1609,500Feb 02 06:22 PM